Immuneering Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IMRX Nasdaq 2830 immuneering.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immuneering Corporation

Immuneering Appoints Andrew Gengos as Chief Financial Officer - Jun 15th, 2026 5:30 am
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Jun 12th, 2026 7:48 am
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - Jun 11th, 2026 5:30 am
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Jun 1st, 2026 1:58 pm
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - Jun 1st, 2026 5:30 am
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - May 21st, 2026 3:00 pm
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - May 15th, 2026 5:35 am
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - May 6th, 2026 8:53 am
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting - Apr 21st, 2026 2:05 pm
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - Apr 20th, 2026 7:00 am
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears - Apr 14th, 2026 1:02 am
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - Apr 6th, 2026 2:05 pm
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - Mar 17th, 2026 2:35 pm
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Mar 9th, 2026 9:15 am
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Mar 6th, 2026 5:45 am
Immuneering to Present at the Leerink Global Healthcare Conference - Mar 2nd, 2026 2:05 pm
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Feb 28th, 2026 12:07 am
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 18th, 2026 2:05 pm
Director of Immuneering Picks Up 1.8% More Stock - Jan 16th, 2026 4:02 am
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Jan 11th, 2026 8:09 am